StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2019, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sat, 16 Feb 2019 17:14:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html for the full story. http://www.streetinsider.com/Press+Releases/Pivotal+Phase+III+Data+for+BAVENCIO%C2%AE+%28avelumab%29+Plus+INLYTA%C2%AE+%28axitinib%29+in+Advanced+Renal+Cell+Carcinoma+Published+in+the+New+England+Journal+of+Medicine/15145300.html Sat, 16 Feb 2019 17:14:00 -0400 A.09642568 A.20600674 A.20986375 A.22847412 A.31066700 A.32727947 A.35044598 A.60001765 MKKGY MRK MRK PFE SEO Merck KGaA Grants Exclusive License to Vertex (VRTX) for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html for the full story. http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Thu, 24 Jan 2019 08:04:53 -0400 MKKGY SEO VRTX Merck KGaA Grants Exclusive License to Vertex (VRTX) for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html for the full story. http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Thu, 24 Jan 2019 08:04:53 -0400 MKKGY SEO VRTX Merck KGaA Grants Exclusive License to Vertex (VRTX) for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html for the full story. http://www.streetinsider.com/Corporate+News/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Thu, 24 Jan 2019 08:04:53 -0400 MKKGY SEO VRTX Merck KGaA Grants Exclusive License to Vertex (VRTX) for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Visit StreetInsider.com at http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html for the full story. http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Thu, 24 Jan 2019 08:04:53 -0400 MKKGY SEO VRTX Merck KGaA Grants Exclusive License to Vertex (VRTX) for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Visit StreetInsider.com at http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html for the full story. http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Thu, 24 Jan 2019 08:04:53 -0400 MKKGY SEO VRTX Merck KGaA Grants Exclusive License to Vertex (VRTX) for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Visit StreetInsider.com at http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html for the full story. http://www.streetinsider.com/Management+Comments/Merck+KGaA+Grants+Exclusive+License+to+Vertex+%28VRTX%29+for+Two+DNA+Damage+Response+Inhibitors/15035091.html Thu, 24 Jan 2019 08:04:53 -0400 MKKGY SEO VRTX Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html for the full story. http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Thu, 24 Jan 2019 08:00:00 -0400 A.20600674 A.20986375 A.35044598 MKKGY MRK MRK SEO VRTX Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html for the full story. http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Thu, 24 Jan 2019 08:00:00 -0400 A.20600674 A.20986375 A.35044598 MKKGY MRK MRK SEO VRTX Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html for the full story. http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Thu, 24 Jan 2019 08:00:00 -0400 A.20600674 A.20986375 A.35044598 MKKGY MRK MRK SEO VRTX Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html for the full story. http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Thu, 24 Jan 2019 08:00:00 -0400 A.20600674 A.20986375 A.35044598 MKKGY MRK MRK SEO VRTX Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html for the full story. http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Thu, 24 Jan 2019 08:00:00 -0400 A.20600674 A.20986375 A.35044598 MKKGY MRK MRK SEO VRTX Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html for the full story. http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany%2C+Grants+Exclusive+License+to+Vertex+for+Two+DNA+Damage+Response+Inhibitors/15035042.html Thu, 24 Jan 2019 08:00:00 -0400 A.20600674 A.20986375 A.35044598 MKKGY MRK MRK SEO VRTX